Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy

Summary What is known and Objective It is now estimated that about 5% of cetuximab‐treated patients and about 3% of panitumumab‐treated patients will develop grade 3–4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)‐targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution. Methods A 2‐year retrospective study was carried out. At least four doses of weekly cetuximab or two doses of bi‐weekly panitumumab were required for inclusion. Serum magnesium profiles were reviewed from 1 month before treatment until 3 months after treatment discontinuation, and patients with